Biotech · Private company
Oyster Point Pharma, Inc.
Track this companyFree. Adds Oyster Point Pharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials120 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- OC-01 (varenicline) nasal sprayPhase 3 · Dry Eye Disease (DED)ClinicalTrials.gov · fetched Nov 12, 2026
- OC-01 High Dose, 1.2 mg/mLPhase 3 · Long Term Follow up Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- OC-01 Low Dose, 0.12 mg/mLPhase 3 · Long Term Follow up Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- OC-01 Mid Dose, 0.6 mg/mLPhase 3 · Long Term Follow up Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)Phase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)Phase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)Phase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- OC-01 (varenicline) nasal sprayPhase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- OC-01 (varenicline) nasal spray 1.2 mg/mlPhase 2 · Neurotrophic KeratopathyClinicalTrials.gov · fetched Nov 12, 2026
- OC-02 (simpinicline) nasal sprayPhase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mgPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mgPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Nasal GuideDry EyeClinicalTrials.gov · fetched Nov 12, 2026
- Tyrvaya Nasal PumpDry EyeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- A Study Evaluating the Safety of the Nasal PumpPHASE4 · TERMINATED · started Feb 21, 2024ClinicalTrials.gov NCT06329687 · fetched Nov 12, 2026
- Phase 4 Study Evaluating the Safety of the Nasal Guide With TyrvayaPHASE4 · COMPLETED · started Jun 14, 2023ClinicalTrials.gov NCT05918406 · fetched Nov 12, 2026
- Nasal Spray Study in Sjogren's Dry Eye DiseasePHASE4 · COMPLETED · started May 1, 2023ClinicalTrials.gov NCT05700422 · fetched Nov 12, 2026
- An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal SensitivityUNKNOWN · started Jul 1, 2022ClinicalTrials.gov NCT05566717 · fetched Nov 12, 2026
- Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic KeratopathyPHASE2 · COMPLETED · started Jun 17, 2021ClinicalTrials.gov NCT04957758 · fetched Nov 12, 2026
- Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered VareniclinePHASE1 · COMPLETED · started Aug 26, 2019ClinicalTrials.gov NCT04072146 · fetched Nov 12, 2026
- Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseasePHASE3 · COMPLETED · started Jul 23, 2019ClinicalTrials.gov NCT04036292 · fetched Nov 12, 2026
- Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland StimulationPHASE2 · COMPLETED · started Sep 25, 2018ClinicalTrials.gov NCT03688802 · fetched Nov 12, 2026
- Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseasePHASE2_PHASE3 · COMPLETED · started Aug 15, 2018ClinicalTrials.gov NCT03920215 · fetched Nov 12, 2026
- Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseasePHASE2 · COMPLETED · started Aug 15, 2018ClinicalTrials.gov NCT03636061 · fetched Nov 12, 2026
- Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)PHASE2 · COMPLETED · started Aug 14, 2018ClinicalTrials.gov NCT03633461 · fetched Nov 12, 2026
- Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)PHASE2 · COMPLETED · started Feb 27, 2018ClinicalTrials.gov NCT03452397 · fetched Nov 12, 2026